CAL-101

CAL-101 Struktur
1146702-54-6
CAS-Nr.
1146702-54-6
Englisch Name:
CAL-101
Synonyma:
Idelalisib;GS-1101, Idelalisib;CAL-101 (GS-1101, Idelalisib);5-fluoro-3-phenyl-2-((1s)-1-(1h-purin-6-ylamino)ethyl)-4(3h)...
CBNumber:
CB62638450
Summenformel:
C22H18FN7O
Molgewicht:
415.4230232
MOL-Datei:
1146702-54-6.mol

CAL-101 Eigenschaften

Sicherheit

CAL-101 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Idelalisib is an orally available selective and potent phosphatidylinositol 3-kinase δ (PI3 Kδ) inhibitor originally developed by Calistoga Pharmaceuticals, which was acquired by Gilead in April 2014. In July 2014, the drug was approved in the USA for the treatment of relapsed chronic lymphocytic leukemia as well as several oncology orphan drug designations. Since idelalisib specifically inhibits PI3Kd, which is expressed primarily in bloodcell lineages, the therapeutic effect is localized, limiting interference with PI3K isoform signaling that is critical to normal function of healthy cells.

Indications

Among the large groups of structural diverse lipid kinase inhibitors, especially against PI3Ks, idelalisib (Zydelig(R), Gilead Sciences) is the only inhibitor approved by FDA for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab and patients with relapsed follicular B-cell non-Hodgkin lymphoma or small lymphocytic lymphoma.

Trademarks

Zydelig

Synthese

Commercial 2-fluoro-6-nitrobenzoic acid (117) was treated with oxalyl chloride in the presence of catalytic amount of N,Ndimethylformamide (DMF) in DCM to give the corresponding 2- fluoro-6-nitrobenzoyl chloride as a brown syrup, which was subsequently coupled with aniline under Schotten-Baumann conditions to yield 2-fluoro-6-nitro-N-phenylbenzamide 118 in 99% yield. Coupling of 118 with commercial N-Boc-2(S)-aminobutyric acid in the presence of Et3N in DCM generated imide 119 in 66% yield. Reductive cyclization of nitro imide 119 by means of zinc dust in acetic acid gave the cyclized quinazolinone 120 in 69% yield, which underwent immediate N-deprotection with TFA in DCM to furnish the corresponding free amine 121. Finally, a substitution reaction involving amine 121 and 6-bromopurine (122) in the presence of DIPEA in t-BuOH gave idelalisib (XV) as a solid in 50% yield.

Synthesis_1146702-54-6

CAL-101 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


CAL-101 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 52)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32686 60
Fuxin Pharmaceutical
+86-021-021-50872116 +8613122107989
contact@fuxinpharm.com China 10297 58
Career Henan Chemica Co
+86-0371-86658258 15093356674;
laboratory@coreychem.com China 30255 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471
sales@sarms4muscle.com China 10523 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418684 +8618949823763
sales@tnjchem.com China 25363 58
Golden Pharma Co., Limited
+undefined18958062155
sales@zjgoldpharm.com China 5905 58
TargetMol Chemicals Inc.
+1-781-999-5354
support@targetmol.com United States 19973 58
Wuhan Topule Biopharmaceutical Co., Ltd
+8618327326525
masar@topule.com China 8474 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +8617865335152
Mandy@hangyubiotech.com China 11013 58
LEAPCHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 43348 58

  • CAL-101 (GS-1101, Idelalisib)
  • GS-1101, Idelalisib
  • Idelalisib
  • 5-fluoro-3-phenyl-2-((1s)-1-(1h-purin-6-ylamino)ethyl)-4(3h)...
  • 1146702-54-6
Copyright 2019 © ChemicalBook. All rights reserved